Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axovant Sciences Ltd.

Division of Roivant Sciences GMBH
www.axovant.com

Latest From Axovant Sciences Ltd.

Appointments: Changes At Axovant Sciences, Immunocore, Sangamo Therapeutics, Circassia, MaxCyte and CANbridge Life Sciences

Pharma and biotech appointments this week include a management shake up at Axovant Sciences, a new CEO at Immunocore, Sangamo's latest legal hire, and new board members at Circassia and MaxCyte.
Appointments BioPharmaceutical

Hung Out As Axovant Rebuilds Its Pipeline, Expands Focus Beyond Dementia

CEO Hung resigns after less than a year; he and several others leave behind a dementia-focused specialty pharma that will return to its entrepreneurial roots to build a broader neuroscience pipeline. Parent company Roivant turns to a less conventional choice, Parvan Cheruvu, to take the helm.

Leadership Business Strategies

What Takeda's Failed TOMMORROW Trial Means For Early Alzheimer's Today

The TOMMORROW study was revolutionary for its time in testing Actos early, before symptoms are apparent; failure is disappointing but similar metabolic approaches might still play a role, says the Alzheimer's Association.

Clinical Trials Neurology

Which Biotechs Enjoyed A 'JPM Jump' - And Which Lost Out?

As participants from this year’s J.P. Morgan Healthcare conference recover from the torrent of new information they were exposed to, Scrip explores which biotechs saw a sustainable shift in their valuations.

Commercial Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Roivant Neurosciences Ltd.
  • Ownership
  • Public
  • Headquarters
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Roivant Sciences GMBH
  • Senior Management
  • David Hung, MD, CEO
    Gregory Weinhoff, CFO
    Lawrence T Friedhoff, MD, Chief Dev. Officer
    Mark Altmeyer, Pres. & Chief Commercial Officer
  • Contact Info
  • Axovant Sciences Ltd.
    Phone: 441 824 8100
    2 Church St., Clarendon House
    Hamilton, Bermuda, HM 11
Advertisement
Advertisement
UsernamePublicRestriction

Register